Pemetrexed in Advanced Non-small Cell Lung Cancer

Armando Santoro, MD

Status: Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

Study type: Observational

Funder types: Other

Identifiers

NCT01193959

ONC/OSS-02/2010

Details and patient eligibility

About

Present study is aimed at investigating potential molecular predictors of sensitivity or resistance to single-agent pemetrexed in the ≥ second line setting in a large cohort of advanced non-small cell lung cancer (NSCLC) patients. The following biomarkers will be investigated with either immunohistochemistry, fluorescence in situ hybridization or genotyping: thymidylate synthase (TS), dihydrofolate reductase (DHFR), glycinamide ribonucleotide formyl transferase (GARFT), aminoimidazole carboxamide ribonucleotide formyltransferase (ATIC/AICARFT), epidermal growth factor receptor (EGFR), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS), v-myc myelocytomatosis viral oncogene homolog (MYC) and phosphoinositide-3-kinase, catalytic, alpha polypeptide (PIK3CA).

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically confirmed diagnosis of advanced non-small cell lung cancer - Tumor tissue available at our institution
• Patients treated with single agent pemetrexed for metastatic disease
• Availability of full clinical data

Exclusion criteria

• Cytological diagnosis of advanced Non-small cell lung cancer
• Lack of tumor tissue at our institution
• Lack of full clinical data